Business Context and Reporting Period
This Form 8-K Current Report was filed by Palisade Bio, Inc. on September 27, 2024, regarding events occurring on September 25, 2024. The filing discloses the entry into a revised employment agreement with J.D. Finley, the Company's Chief Executive Officer and Chief Financial Officer.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation terms.
Material Changes and Agreement Terms
The Company entered into a new at-will employment agreement with J.D. Finley. The filing explicitly states that the agreement does not increase Mr. Finley's current base salary or target bonus. Key terms include:
- Base Salary: $542,000 per year.
- Annual Cash Bonus: Target of up to 50% of base salary, contingent on performance goals.
- Equity: Eligible for annual market-based stock option grants as determined by the Board.
- Severance (Standard): Upon termination without "Cause" or resignation for "Good Reason," Mr. Finley is eligible for 12 months of base salary and COBRA benefits.
- Severance (Change in Control): If termination occurs within the Change in Control Period, benefits increase to 18 months of base salary, 100% of the target bonus, 18 months of COBRA, and immediate acceleration of 100% of time-based vested equity awards.
All severance benefits are contingent upon the execution of a release of claims satisfactory to the Company.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, operational outlook, or management commentary on business strategy. The primary risk disclosed relates to the potential future cash outflow associated with the severance provisions, particularly the accelerated equity vesting and lump-sum payments triggered by a Change in Control.
Investor Verification Checklist
- Verify the definitions of "Cause" and "Good Reason" in the full Employment Agreement (Exhibit 10.01) to understand the specific triggers for severance.
- Confirm the current status of Mr. Finley's outstanding equity awards to assess the potential cost of immediate acceleration.
- Review the Company's cash position to evaluate its ability to fund the potential 18-month severance package in a Change in Control scenario.
- Check for any other concurrent filings that might indicate a pending Change in Control transaction.